Alternative names:

DOP, DOR, DOR1, OPRD

Description:

Human OPRD full length protein-synthetic nanodisc

Background:

G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.[UniProtKB/Swiss-Prot Function]

Protein families:

Transmembrane,Druggable Genome,

Protein pathways:

GPCRDB Class A Rhodopsin-like,Peptide GPCRs,Autoimmune & Inflammatory Response,G-Protein Coupled Receptors Signaling Pathway,Na2 /NF-AT Signaling Pathways,

Expression host:

HEK293

Target:

OPRD

Molecular weight:

The human full length OPRD protein has a MW of 40.4kDa

Formulation / Reconstitution:

Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.

Usage:

Research use only

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com